Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$226.97
+3.6%		$284.89
$197.81
▼
$495.55
$30.32B0.31.40 million shs947,304 shs
Biogen Inc. stock logo
BIIB
Biogen
$208.98
+0.3%		$201.70
$127.00
▼
$219.72
$30.86B0.171.28 million shs267,287 shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$79.26
+0.8%		$78.78
$32.89
▼
$88.31
$9.83B0.382.16 million shs367,642 shs
Natera, Inc. stock logo
NTRA
Natera
$274.79
-0.1%		$249.60
$135.75
▼
$288.04
$39.45B1.511.34 million shs361,917 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-0.61%-24.07%-29.99%-27.73%-47.81%
Biogen Inc. stock logo
BIIB
Biogen
+3.29%+1.38%-3.55%+9.32%+57.68%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+2.83%-1.06%-9.11%+5.04%+114.90%
Natera, Inc. stock logo
NTRA
Natera
+1.79%+9.11%-1.48%+27.94%+101.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$226.97
+3.6%		$284.89
$197.81
▼
$495.55
$30.32B0.31.40 million shs947,304 shs
Biogen Inc. stock logo
BIIB
Biogen
$208.98
+0.3%		$201.70
$127.00
▼
$219.72
$30.86B0.171.28 million shs267,287 shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$79.26
+0.8%		$78.78
$32.89
▼
$88.31
$9.83B0.382.16 million shs367,642 shs
Natera, Inc. stock logo
NTRA
Natera
$274.79
-0.1%		$249.60
$135.75
▼
$288.04
$39.45B1.511.34 million shs361,917 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
-0.61%-24.07%-29.99%-27.73%-47.81%
Biogen Inc. stock logo
BIIB
Biogen
+3.29%+1.38%-3.55%+9.32%+57.68%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+2.83%-1.06%-9.11%+5.04%+114.90%
Natera, Inc. stock logo
NTRA
Natera
+1.79%+9.11%-1.48%+27.94%+101.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.92
Moderate Buy$396.7274.79% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.56
Moderate Buy$224.617.48% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.95
Moderate Buy$99.9026.03% Upside
Natera, Inc. stock logo
NTRA
Natera
2.82
Moderate Buy$267.83-2.53% Downside

Current Analyst Ratings Breakdown

Latest CYTK, NTRA, BIIB, and ALNY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/4/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$410.00 ➝ $315.00
8/4/2026
Biogen Inc. stock logo
BIIB
Biogen
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$221.00 ➝ $241.00
8/3/2026
Biogen Inc. stock logo
BIIB
Biogen
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$200.00 ➝ $215.00
8/3/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$380.00 ➝ $340.00
8/3/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform ➝ Strong-Buy$420.00
8/3/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$527.00 ➝ $450.00
7/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
7/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$485.00 ➝ $455.00
7/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$445.00 ➝ $350.00
7/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$400.00 ➝ $375.00
7/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$400.00 ➝ $300.00
(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$3.71B8.18$2.88 per share78.80$10.12 per share22.43
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.12$23.43 per share8.92$127.56 per share1.64
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$88.04M112.03N/AN/A($5.39) per share-14.71
Natera, Inc. stock logo
NTRA
Natera
$2.31B17.06N/AN/A$12.38 per share22.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$5.3842.1122.74N/A15.26%84.93%14.30%N/A
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6536.9712.726.188.32%11.18%6.88%N/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.63N/AN/AN/A-9.05%-14.74%-10.27%8/6/2026 (Estimated)

Latest CYTK, NTRA, BIIB, and ALNY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.63N/AN/AN/A$17.59 millionN/A
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939N/AN/AN/A$661.24 millionN/A
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
5/5/2026Q1 2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
3.06
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
4.21
4.21
Natera, Inc. stock logo
NTRA
Natera
N/A
2.96
2.83

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Natera, Inc. stock logo
NTRA
Natera
99.90%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.60%
Natera, Inc. stock logo
NTRA
Natera
5.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.66 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250124.43 million121.20 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140143.21 million135.98 millionOptionable

Recent News About These Companies

Natera Files For Japan PMDA Approval Of Signatera Test In Bladder Cancer
 |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69224302-natera-files-for-japan-pmda-approval-of-signatera-test-in-bladder-cancer-020.htm
Quantinno Capital Management LP Raises Holdings in Natera, Inc. $NTRA
August 4 at 4:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-raises-holdings-in-natera-inc-ntra-2026-08-04/
Roxbury Financial LLC Grows Stock Holdings in Natera, Inc. $NTRA
August 3 at 6:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-roxbury-financial-llc-grows-stock-holdings-in-natera-inc-ntra-2026-08-03/
Amundi Sells 26,895 Shares of Natera, Inc. $NTRA
August 3 at 3:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-amundi-sells-26895-shares-of-natera-inc-ntra-2026-08-03/
NWI Management LP Trims Stock Position in Natera, Inc. $NTRA
August 2 at 6:15 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-nwi-management-lp-trims-stock-position-in-natera-inc-ntra-2026-08-02/
Royal Bank of Canada Increases Position in Natera, Inc. $NTRA
August 2 at 5:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-royal-bank-of-canada-increases-position-in-natera-inc-ntra-2026-08-02/
8,051 Shares in Natera, Inc. $NTRA Acquired by Healthcare of Ontario Pension Plan Trust Fund
August 2 at 5:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-8051-shares-in-natera-inc-ntra-acquired-by-healthcare-of-ontario-pension-plan-trust-fund-2026-08-02/
Natera (NTRA) Sets Earnings Date, Is The Stock Fully Priced?
August 1, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/natera-ntra-sets-earnings-date-091312632.html
California State Teachers Retirement System Sells 4,104 Shares of Natera, Inc. $NTRA
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-sells-4104-shares-of-natera-inc-ntra-2026-08-01/
John Fesko Sells 782 Shares of Natera (NASDAQ:NTRA) Stock
July 30, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ntra-insider-buying-and-selling-2026-07-30/
Oddo BHF Asset Management Sas Makes New $6.41 Million Investment in Natera, Inc. $NTRA
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-oddo-bhf-asset-management-sas-makes-new-641-million-investment-in-natera-inc-ntra-2026-07-30/
Natera (NTRA) to Post Quarterly Earnings on Thursday
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/natera-ntra-to-post-quarterly-earnings-on-thursday-2026-07-30/
Bull Harbor Capital LLC Invests $1.54 Million in Natera, Inc. $NTRA
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bull-harbor-capital-llc-invests-154-million-in-natera-inc-ntra-2026-07-30/
Natera (NASDAQ:NTRA) Insider John Fesko Sells 782 Shares
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/natera-nasdaqntra-insider-john-fesko-sells-782-shares-2026-07-29/
Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 782 Shares of Stock
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/natera-nasdaqntra-cfo-michael-burkes-brophy-sells-782-shares-of-stock-2026-07-29/
Natera (NASDAQ:NTRA) Insider John Fesko Sells 931 Shares of Stock
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/natera-nasdaqntra-insider-john-fesko-sells-931-shares-of-stock-2026-07-29/
Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 1,010 Shares of Stock
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/natera-nasdaqntra-insider-solomon-moshkevich-sells-1010-shares-of-stock-2026-07-29/
Solomon Moshkevich Sells 1,204 Shares of Natera (NASDAQ:NTRA) Stock
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/solomon-moshkevich-sells-1204-shares-of-natera-nasdaqntra-stock-2026-07-29/
Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,863 Shares
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/natera-nasdaqntra-cfo-michael-burkes-brophy-sells-1863-shares-2026-07-29/
Steven Leonard Chapman Sells 2,190 Shares of Natera (NASDAQ:NTRA) Stock
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/steven-leonard-chapman-sells-2190-shares-of-natera-nasdaqntra-stock-2026-07-29/
Insider Selling: Natera (NASDAQ:NTRA) CFO Sells $614,329.24 in Stock
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-natera-nasdaqntra-cfo-sells-61432924-in-stock-2026-07-29/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Illuminated AV logo displayed on a riveted metal panel surrounded by cables and machinery components.
AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
By Jeffrey Neal Johnson | July 10, 2026
A Patriot missile launcher and soldier on an airbase tarmac as an F-35 fighter jet flies overhead at sunset.
RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
By Dan Schmidt | July 26, 2026
A red downward-pointing zigzag arrow emerges from a tablet screen displaying a falling stock chart, symbolizing market declines and negative financial momentum.
Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors
By Thomas Hughes | July 6, 2026
Fighter jet fuselage with cockpit in a hangar displaying the Lockheed Martin logo.
Lockheed Martin Secures the Ultimate Defense Moat
By Jeffrey Neal Johnson | July 9, 2026
Steam rises from a power plant cooling tower silhouetted against a glowing sunset sky.
3 Energy Stocks Racing to Fix AI's Power Problem
By Bridget Bennett | July 14, 2026
Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$226.97 +7.97 (+3.64%)
As of 12:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen stock logo

Biogen NASDAQ:BIIB

$208.98 +0.53 (+0.25%)
As of 12:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$79.26 +0.65 (+0.83%)
As of 12:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Natera stock logo

Natera NASDAQ:NTRA

$274.79 -0.40 (-0.14%)
As of 12:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas